You are here
The Alliance for Regenerative Medicine Announces Agenda and Legislator of the Year Award Recipients for Ninth Annual Dinner and Legislative Fly-In
WASHINGTON, DC, May 15, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) announced the speaker line up for its ninth Annual Dinner and Legislative Fly-In, to be held May 22 and 23 in Washington, D.C. This event honors recent accomplishments in the sector and enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.
On May 22, ARM’s RMAT Policy Lunch includes a keynote address by FDA Commissioner Dr. Scott Gottlieb, who will detail the agency’s regulatory framework for regenerative medicine products including implementation of the Regenerative Medicine Advanced Therapy (RMAT) designation, new agency guidance for product developers, and other initiatives. ARM CEO Janet Lambert will provide a mid-year update on the industry’s legislative and clinical progress to date as well as a forecast of anticipated achievements and challenges. The programming will also include a multi-stakeholder discussion featuring the patient perspective on the promise of regenerative medicine.
Following the day’s events, ARM’s Annual Dinner will host more than 150 guests in an intimate gathering to recognize key corporate, scientific, and policy leaders in this sector, including patients and patient advocates, disease-foundation executives, and other industry champions. Attendees will have the opportunity to network, celebrate the previous year’s many accomplishments and hear from the evening’s featured speakers, Ron Bartek, Co-Founder and Founding President, Friedreich’s Ataxia Research Alliance; Marshall Summar, Director, Rare Disease Institute, Children’s National Medical Center; and Jean Walsh, Patient Advocate and Ambassador; Friedreich’s Ataxia Research Alliance.
The lead sponsor for this year’s event is Pfizer, with supporting sponsors Aldevron, Cognate BioServices, CTI Clinical Trials & Consulting, Precision BioSciences, and Shire. The table hosts are Millipore Sigma and Janssen R&D. ARM is organizing the Legislative Fly-In in collaboration with the American Society for Gene and Cell Therapy.
ARM also announced its “Legislator of the Year” award recipients, recognition given annually to key lawmakers who have demonstrated recent and substantial leadership in advancing this sector. This year, ARM will present the award to U.S. Senator Michael Bennett (D-CO) and U.S. Representative Michael Burgess (R-TX) in honor of their leadership and bipartisanship on key healthcare issues. Senator Bennett is a member of the Senate Health, Education, Labor, and Pensions (HELP) Committee and Congressman Burgess, the most senior medical doctor currently serving in Congress, is a member of the House Energy and Commerce Committee and the chairman of the Subcommittee on Health.
The following day, May 23, ARM members will participate in the organization’s annual Legislative Fly-In. Members will form state delegations to meet with key members of Congress to describe the immense near-term potential of gene and cellular therapies and the need for legislation that supports the development of life-saving treatments.
The Annual Dinner will be held at the InterContinental Washington, D.C. – The Wharf and is open to the public, however registration is required. Complimentary registration is available to credentialed members of the media, please contact Lyndsey Scull (firstname.lastname@example.org) for more information.
ARM’s Legislative Fly-In is limited to members of the organization and registration is also required. To register and for more information about this event, please visit https://alliancerm.org/event/annualdinner. Please contact Chelsey Hathaway (email@example.com) with any questions about this event.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
CONTACT: The Alliance for Regenerative Medicine Lyndsey Scull 202 213 7086 firstname.lastname@example.org